Scholars Central

CommentaryPublished 2015

Ketamine: An Update for Its Use in Complex Regional Pain Syndrome and Major Depressive Disorder

Authors: William E Bentley, Michael Sabia, Michael E Goldberg, Irving W Wainer

Journal of Clinical & Experimental Pharmacology

Volume 5 · Issue 2 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Abstract In recent years, there has been significant research in regard to the efficacy of ketamine in regards to treating Complex Regional Pain Syndrome (CRPS) and Major Depressive Disorder (MDD). Many patients have had substantial symptomatic relief; however, not all patients have had positive results. This has prompted current research with evidence to suggest certain biomarkers exist that would infer which patients will/will not respond to ketamine treatment. Current biomarkers of interest include D-Serine (D-Ser) and magnesium, which will be discussed. Whether or not D-Ser and/or magnesium levels should be checked and possibly dictate therapy is an area of future research. It is also possible that downstream metabolites of ketamine are the key to successful therapy

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Pharmacology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pharmacology
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “William E Bentley”
  • BylineArticles whose byline prints “Michael Sabia”
  • BylineArticles whose byline prints “Michael E Goldberg”
  • BylineArticles whose byline prints “Irving W Wainer”